| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911182 | Lung Cancer | 2013 | 8 Pages |
Abstract
Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-naïve, unselected advanced NSCLC patients. Clinical trials identifier: NCT00991796.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Martin Reck, Maciej Krzakowski, Ewa Chmielowska, Martin Sebastian, Dietrich Hadler, Tara Fox, Qiang Wang, Jon Greenberg, Robert A. Beckman, Joachim von Pawel,